Detall de la convocatòria
Característiques
| Característica |
|---|
|
Objectiu de la convocatòria
This grant program supports research on ALK-positive lung cancer, particularly studies on ALK rearrangements and the development of new therapeutic approaches. Proposals linked to an ongoing or planned clinical trial are preferred. |
|
Característiques principals
Project topics include, but are not limited to: - Understanding why some ALK-positive lung cancers progress more rapidly - Investigating the role of leptomeningeal disease - Mechanisms of tumor persistence, including persister cells - Effects of additional mutations (e.g., MET) on tumor biology and treatment resistance - Differential treatment responses across ALK variants - Approaches to reprogram or modulate the tumor microenvironment to enhance immune activity - Identifying metabolic pathways essential for ALK-positive tumor survival - Strategies to improve immunotherapy efficacy or stimulate immune recognition of ALK-positive tumors - Development of vaccines, cell therapies, and other innovative therapeuticapproaches |
|
Lloc de presentació
HMRIB and PSMAR staff who need more information should contact: Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00. Carol Barnwell: [email protected] Ext.: 1670 Marta López: [email protected] Ext.: 1576 Júlia Vidal: [email protected] Ext.: 1736 |
|
Convocatòria (URL)
https://www.lungcancerresearchfoundation.org/research/funding-opportunities-2026/ |
|
Informació addicional
The call follows a two-stage application process, and applications must be submitted through ProposalCentral. |
|
Requisits
|
|
Dotació
$150,000 per year |
|
Durada
Two years |
Arxius
| Arxiu |
|---|
| 2026-ALK-grant-RFP.pdf |